The Chemotherapy Induced Anemia drugs in development market research report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chemotherapy Induced Anemia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued products.

GlobalData tracks 18 drugs in development for Chemotherapy Induced Anemia by 19 companies/universities/institutes. The top development phase for Chemotherapy Induced Anemia is preclinical with seven drugs in that stage. The Chemotherapy Induced Anemia pipeline has 18 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Chemotherapy Induced Anemia pipeline products market are: Sumitomo Dainippon Pharma Oncology, Astellas Pharma and PhytoHealth.

The key targets in the Chemotherapy Induced Anemia pipeline products market include Erythropoietin Receptor (EPOR), Egl Nine Homolog 1 (Hypoxia Inducible Factor Prolyl Hydroxylase 2 or Prolyl Hydroxylase Domain Containing Protein 2 or SM 20 or EGLN1 or EC, and Iron.

The key mechanisms of action in the Chemotherapy Induced Anemia pipeline product include Erythropoietin Receptor (EPOR) Agonist with nine drugs in Pre-Registration. The Chemotherapy Induced Anemia pipeline products include three routes of administration with the top ROA being Oral and five key molecule types in the Chemotherapy Induced Anemia pipeline products market including Small Molecule, and Recombinant Protein.

Chemotherapy Induced Anemia overview

Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain, dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions, and/or depression associated with anemia. The predisposing factors include age, co-morbidities, and the time course of the chemotherapy.

For a complete picture of Chemotherapy Induced Anemia’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.